Table 1.
Crude Odds Ratio (95% CI) |
No. persistent/ no. transient |
|
---|---|---|
Site of incident detection (n=125‡) | ||
Cervix only | 1.00 | 1/8 |
Vulva/vagina only | 10.78 (1.20–96.67) | 31/23 |
Both cervix and vulva/vagina | 15.62 (1.89–129.25) | 41/21 |
HPV risk group | ||
Low- or undetermined-risk | 1.00 | 31/24 |
High-risk | 1.12 (0.51–2.48) | 45/31 |
Number of concurrent HPV types detected§ | ||
0 | 1.00 | 18/14 |
≥1 | 1.10 (0.47–2.60) | 58/41 |
Current smoker§ | ||
No | 1.00 | 68/53 |
Yes | 3.12 (0.37–26.37) | 8/2 |
Currently using hormonal contraceptives§ | ||
No | 1.00 | 35/17 |
Yes | 0.52 (0.24–1.16) | 41/38 |
Last reported vaginal intercourse§ (n=127‖) | ||
>2 days before testing | 1.00 | 17/16 |
≤2 days before testing | 0.72 (0.31–1.69) | 56/38 |
Sex partner(s) in the prior 8 months§ |
||
No sex partners | 1.00 | 1/3 |
Non-new sex partners only | 2.25 (0.16–31.11) | 9/12 |
≥1 new sex partner(s) | 4.95 (0.41–60.15) | 66/40 |
Total no. of sex acts in the prior 8 months§ (n=123)** | ||
0 | 1.00 | 1/3 |
1–16 | 4.69 (0.39–55.96) | 25/16 |
17–41 | 4.80 (0.35–65.64) | 24/15 |
42+ | 3.16 (0.24–41.89) | 20/19 |
No. of condom-unprotected sex acts in the prior 8 months§ (n=119)**†† |
||
0 | 1.00 | 9/6 |
1–6 | 1.19 (0.39–3.67) | 25/14 |
7–25 | 1.47 (0.35–6.10) | 22/10 |
26+ | 0.43 (0.12–1.57) | 13/20 |
Sex partner(s) after incident infection‡‡ | ||
No sex partners | 1.00 | 15/14 |
Non-new sex partners only | 1.14 (0.47–2.74) | 39/32 |
≥1 new sex partner(s) | 2.28 (0.82–6.38) | 22/9 |
Total no. of sex acts after incident infection‡‡ | ||
0 | 1.00 | 15/14 |
1–11 | 1.44 (0.54–3.79) | 20/13 |
12–27 | 1.87 (0.70–4.95) | 24/12 |
28+ | 0.99 (0.32–3.05) | 17/16 |
No. of condom-unprotected sex acts with a non-new partner after incident infection‡‡ (n=102) §§ |
||
0 | 1.00 | 18/12 |
1–8 | 2.00 (0.52–7.63) | 18/6 |
9–22 | 0.73 (0.21–2.49) | 12/11 |
23+ | 0.73 (0.25–2.08) | 13/12 |
Persistent detections included all incident type-specific positives that were followed by two consecutive type-specific positives (+++).
Transient detections included all incident type-specific positives that were followed by two consecutive type-specific negatives (+−−).
6 infections that were first detected in the self-collected sample only were excluded.
At time of incident detection.
4 infections were detected in women who reported vaginal intercourse on the day of HPV testing. Because data on time of vaginal intercourse was not collected, it was not possible to determine whether vaginal intercourse occurred before or after testing. Therefore, those 4 infections were excluded.